Blood
Articles in this Issue
Efficacy and safety of hetrombopag in the treatment of Pediatric immune thrombocytopenia: A Real-World Observational Study
Abstract Background Hetrombopag, an oral thrombopoietin receptor agonist (TPO-RA), has been approved to increase platelet counts and reduce...
Prophylaxis with thiotepa and high-dose methotrexate showed lower central nervous system relapse rate in high-risk diffuse large B-cell lymphoma
Abstract Background: Central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) confers a dismal prognosis....
Stepwise engineering of human germinal center B cells to model dark zone high-grade B cell lymphoma driven by sequential BCL2 and MYC deregulation
Abstract High-grade B-cell lymphomas (HGBCL) encompass a heterogeneous group of aggressive B-cell malignancies. The most common genetically...
Real-world experience of voxelotor treatment in patients with sickle cell disease
Abstract Introduction: Sickle cell disease (SCD) is an inherited blood disorder marked by hemolysis and frequent vaso-occlusion, leading to...
Osteoblasts differentiated from FVIII-deficient mice exhibit impaired mineralization capacity and promote excessive in vitro osteoclastogenesis
Abstract Background. Factor VIII (FVIII) has recently received increasing attention for its roles beyond the coagulation cascade. Indeed, FVI...
Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial
Abstract Background Richter transformation (RT), the development of diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) in patien...
Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma
Abstract Introduction: Ciltacabtagene autoleucel (cilta-cel) has demonstrated deep and durable responses in relapsed/ref...
Gingerol ameliorates chronic graft-versus-host disease by regulating treg/Th17 transdifferenciation
Abstract Gingerol reprograms T helper cell differentiationvia P2RY13 suppression to attenuate chronic Graft-versus-host disease Background:...
Real-world clinical trial of hetrombopag (TPO-RA) in the treatment of primary immune thrombocytopenia (ITP)
Abstract Background: Primary immune Thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disorder characterized by isolated peripher...
Blood product transfusions for pediatric Jehovah's witness patients: Management recommendations and considerations
Abstract The Jehovah's witness faith precludes patients from consenting to blood transfusions. This presents a therapeutic challenge for ped...
Glofitamab-based combinatorial therapy demonstrates high efficacy in primary refractory and early relapsed DLBCL: Real-world evidence of durable responses and immune modulation in high-risk subgroups
Abstract Background: Glofitamab, an innovative CD20xCD3 bispecific T-cell engager, has emerged as a groundbreaking therapeutic option for re...
Structure guided targeting of the GATAD2A-CHD4 interaction in the MBD2-NuRD complex results in high levels of HbF
Abstract It is well established that high levels of fetal hemoglobin (HbF) can overcome the pathophysiologic defects in sickle cell disease...
Outcomes with prophylactic anticoagulation in hemolytic anemias: A systematic review
Abstract Introduction: Venous thromboembolism (VTE) is one of the most common causes of mortality in hemolytic anemias,...
Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study
Abstract Introduction: Epcoritamab (epco) and glofitamab (glofit) are bispecific antibodies (BsAbs) approved for the treatment of patients (...
The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study
Abstract Background The combination of chemotherapy and blinatumomab (blina) in the frontline setting for Philadelphia-negative B-cell acute...
First-line treatment in patients with transplant-ineligible, newly diagnosed multiple myeloma by age, frailty, and comorbidity
Abstract Introduction: New treatments offer hope for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for high-dose...
We know what we need: Exploring the communicative and structural gaps in support for caregivers of adults with sickle cell disease (CASPS)
Abstract Background Despite advancements in Sickle Cell Disease (SCD) treatment, systems of care continue to neglect the critical role of ca...
Maintenance therapy in AML: A meta-analysis and a single center retrospective study
Abstract Introduction Over the last decade, the overall survival of AML patients has improved due to steadfast progress in drug development,...
Genetic landscape of pediatric myelodysplastic syndrome in Japan
Abstract Introduction Pediatric myelodysplastic syndrome (MDS) shows distinct features compared to adult MDS, but its ge...
Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma
Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has revolutionized treatment...
Clinical features and outcomes of myeloproliferative neoplasm patients with MPL mutations and concurrent JAK2/calr mutations
Abstract Backgroud Myeloproliferative neoplasms (MPNs) are a group of hematologic malignancies characterized by constitutive activation of t...
Early intervention in smoldering multiple myeloma: A systematic review of comparative prospective trials
Abstract Introduction: Smoldering multiple myeloma (SMM) or asymptomatic myeloma is a precursor to symptomatic multiple...
Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GMMG-HD7 study
Abstract Introduction. In newly diagnosed multiple myeloma (NDMM) patients (pts) eligible for autologous stem-cell transplant (ASCT), the ph...
First-in-human trial of GT719, a novel stem cell-derived allogeneic anti-CD19 CAR-iNKT cell therapy for relapsed/refractory B cell malignancies
Abstract Background and Significance:Adoptive cell therapy, particularly CAR-T therapy, has transformed cancer treatment, showing remarkable...
Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma
Abstract Background: There remains an opportunity for new therapies to improve long-term outcomes for patients with low-tumor burden follicu...